secwatch.observer — SEC 8-K summary
======================================

Issuer:     MADRIGAL PHARMACEUTICALS, INC. (MDGL)
CIK:        0001157601
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0001193125-25-004939
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Madrigal reports preliminary Rezdiffra Q4 2024 net sales $100M–$103M; over 11,800 patients on therapy
--------------------------------------------------------------------------------

- Preliminary Q4 2024 Rezdiffra net sales $100M–$103M, full-year $177M–$180M.
- Year-end cash, equivalents and marketable securities ~$931M.
- Over 11,800 patients on Rezdiffra as of December 31, 2024.
- EMA decision on Rezdiffra MAA expected mid-2025; German launch targeted H2 2025.
- MAESTRO-NASH OUTCOMES trial in compensated cirrhosis fully enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157601/000119312525004939/0001193125-25-004939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157601/000119312525004939/d925380d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer